GlassScriptPhysician profile
Michael Joseph Oneka
NPI 1366457129
$8,746.81
in general payments reported to CMS, 2019-2025
39 companies · $2,523 in 2025
The $2,523 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,244 · 2020: $229 · 2021: $203 · 2022: $869 · 2023: $1,895 · 2024: $1,783 · 2025: $2,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,200.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,439.70 | 2022-2025 | Descovy, Yeztugo, Epclusa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,211.76 | 2021-2025 | Caplyta |
| Viiv Healthcare Company | $1,208.54 | 2022-2025 | Apretude, Rukobia, Dovato |
| Vanda Pharmaceuticals INC. | $718.32 | 2019-2025 | Fanapt |
| Astrazeneca Pharmaceuticals LP | $557.84 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $529.11 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $463.93 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Novo Nordisk INC | $439.07 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $302.06 | 2019-2024 | |
| Lilly USA, LLC | $257.43 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $232.85 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $221.51 | 2019-2020 | |
| Axsome Therapeutics, INC. | $138.71 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $131.38 | 2019 | |
| Amgen INC. | $122.48 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Oneka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.